BD set to add HandyLab to molecular Dx offering
This article was originally published in Clinica
Executive Summary
BD is to grow its portfolio of molecular diagnostics technology by purchasing HandyLab, a specialist in assays and automation platforms. The acquisition will follow on from an exclusive partnership between the two firms whereby BD Diagnostics aims to commercialise its molecular assays on a new platform that will integrate benchtop technology developed by Ann Arbor, Michigan-based HandyLab (www.clinica.co.uk, May 19 2009). BD said that it plans to run its GeneOhm molecular assays for methicillin-resisant Staphylococcus aureus (MRSA), Clostridium difficile and vancomycin-resistant Enterococcus (VRE) onto HandyLab’s platform and market them as the BD MAX system. Financial details of the deal, which is expected to close during the first quarter of fiscal 2010, were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals